Australian Medicines Terminology (AMT)
Single and Multi Component Examples

V 1.71

3 Dec 2009

nehta

National E-Health Transition Authority Ltd
Level 25
56 Pitt Street
Sydney, NSW, 2000
Australia.
www.nehta.gov.au

SNOMED CT copyright notice and trademark acknowledgement

Disclaimer

NEHTA makes the information and other material ("Information") in this document available in good faith but without any representation or warranty as to its accuracy or completeness. NEHTA cannot accept any responsibility for the consequences of any use of the Information. As the Information is of a general nature only, it is up to any person using or relying on the Information to ensure that it is accurate, complete and suitable for the circumstances of its use.

Copyright © 2009, NEHTA.

This document contains information which is protected by copyright. All Rights Reserved.

nehta

Legend used within this document



Document History

Version	Date	Author	Comments
V1.0	14th August 2009	AMT Model Review Group	• IS A relationship between MP and MPP removed • Recursive IS A relationship removed for MP and MPUU • IS A relationship between TP and TPP changed to aggregation has TPUU • Referece set for the following modelled ◊ GTIN ◊ ARTG ID ◊ Subpack quantity ◊ Unit of Use Quantity ◊ Numerator strength ◊ Denominator strength ◊ Subpack quantity • IS A relationship added between form and unit of measure • Is Modification of relationship for substance removed • Has unit of measure relationship between from Form to Unit of Measure
V1.1	25th August 2009	AMT Model Review Group	• IS A relationship between TP and TPP changed back to IS A aggregation has TPUU • IS A revised between Form, Unit of Use and Unit of Measure • Unit of use concept created • IS A relationship added between form and unit of use
V1.2	28th August 2009	AMT Model Review Group	• Is Modification of relationship for substance added back • Unit of Use and Form concepts separated
V1.3	17th September 2009	AMT Model Review Group	• TP and TPG exampled changed (codral) • TP to TPG relationship direction corrected • TP to TPUU relationship type corrected • Has Ingredient relationship to salt where salt if present and relevant
V1.32	30th September 2009	AMT Model Review Group	• History Added • Panadeine Forte relationship corrected
V1.4	30th October 2009	AMT Model Review Group	• Model updated to reflect changes and impacts emerging from IHTSDO decisions on SNOMED CT medicines model. • Annotated version of the model added. • Repetitious example removed to reduce review burden. • Examples updated to reflect the above changes, including a summary of changes made to each. • Further examples added to illustrate population examples of key elements of the model.
V1.6	13th November 2009	AMT Model Review Group	• Removal of recursive TP • Addition of TP has TPP • Removal of TPP is a MPP • Removal of TPP is a CTPP • Addition of CTPP has a TPP
V1.7	27th November 2009	AMT Model Review Group	• Has TPP relationship changed to has TP and direction of relationship reversed • Has CTPP relationship changed to has TP and direction of relationship reversed • Data type changed for unit of use size and unit of use quantity reference sets • Has qualifier relationship added between unit of use quantity and Unit of Measure • Recursive relationship at the MP level removed in AMT model and this is retained in the international model • Cardinality changes for the relationships has dose form, has MPUU, is modification of, has TPUU, has TPP and has container type
V1.71	3rd December 2009	AMT Model Review Group	• Destination of has specific active ingredient relationship for Amoxil example corrected • Has TPUU relationship originates from each CTPP component pack to its TPUU for Nexium Hp 7, ZolaCos CP and Didrocal. • Has MPUU relationship originates from each MPP component pack to its MPUU for Nexium Hp 7, ZolaCos CP and Didrocal. • Has TP relationship between CTPP component packs and TP added for Nexium Hp 7, ZolaCos CP and Didrocal. • Superpack CTPP and TPP terms amended to reflect Didrocal as a combination pack. • The coloured lines representing certain relationships for multi-component examples are to aid readability and have no significance.

Note:
The GTIN, Licence ID and ATC Code have been removed from all examples to preserve space and provide clarity to the MPUU and TPUU relationship without the clutter.

Amoxil



Summary of Changes

1. MP to Substance has_ingredient relationship name updated
2. MPUU to Substance has_ingredient relationship refined
3. MPUU to Substance has_BoSS relationship name updated
4. Substance to Substance is_modification_of relationship added
5. Denominator Strength RefSet added to updated has_BoSS relationship to reflect normalisation
6. Unit of Use Size RefSet added to has_unit_of_use relationship
7. CTPP to TP and TPP to TP relationship name changed.
8. Unit of Measure qualifier added to unit of use quantity.

Atrovent



Summary of Changes

1. Example updated to use a metered dose inhaler.

2. MP to Substance has_ingredient relationship name updated

3. MPUU to Substance has_ingredient relationship refined.

4. Destination of has specific active ingredient relationship is the Substance ipratropium bromide rather than the hydrated form.

5. MPUU to Substance has_BoSS relationship name updated

6. Substance to Substance is_modification_of relationship added

7. Denominator Strength RefSet added to updated has_BoSS relationship to reflect normalisation

8. Unit of Use Size RefSet added to has_unit_of_use relationship

9. CTPP to TP and TPP to TP relationship name changed.

10. Unit of Measure qualifier added to unit of use quantity.

Modecate



Summary of Changes

1. MP to Substance has_ingredient relationship name updated
2. MPUU to Substance has_ingredient relationship refined
3. MPUU to Substance has_BoSS relationship name updated
4. Numerator Strength value changed to reflect normalisation
5. Denominator Strength value changed to reflect normalisation
6. Unit of Use Size RefSet added to has_unit_of_use relationship
7. CTPP to TP and TPP to TP relationship name changed.
8. Unit of Measure qualifier added to unit of use quantity.

Panadeine Forte



Summary of Changes

1. MP to Substance has_ingredient relationship name updated

2. MPUU to Substance has_ingredient relationship refined

3. MPUU to Substance has_BoSS relationship name updated

4. Substance to Substance is_modification_of relationship added

5. Denominator Strength RefSet added to updated has_BoSS relationship to reflect normalisation

6. Unit of Use Size RefSet added to has_unit_of_use relationship

7. CTPP to TP and TPP to TP relationship name changed.

8. Unit of Measure qualifier added to unit of use quantity.

Canesten



Summary of Changes

1. MP to Substance has_ingredient relationship name updated

2. MPUU to Substance has_ingredient relationship refined

3. MPUU to Substance has_BoSS relationship name updated

4. Unit of use size does not exist in this case and for all products with a continuous dose form as a unit of use cannot be quantified.

5. Unit of Use is populated as continuous.

6. CTPP to TP and TPP to TP relationship name changed.

7. Unit of Measure qualifier added to unit of use quantity.

Ferrosig



Summary of Changes

1. MP to Substance has_ingredient relationship name updated
2. MPUU to Substance has_ingredient relationship refined
3. MPUU to Substance has_BoSS relationship name updated
4. Numerator Strength value changed to reflect normalisation
5.Denominator Strength value changed to reflect normalisation
6. Unit of Use Size RefSet added to has_unit_of_use relationship
7. CTPP to TP and TPP to TP relationship name changed.
8. Unit of Measure qualifier added to unit of use quantity.

Amoxil, Alphamox and Moxacin



Summary of Changes

1. MP to Substance has_ingredient relationship name updated
2. MPUU to Substance has_ingredient relationship refined
3. MPUU to Substance has_BoSS relationship name updated
4. Substance to Substance is_modification_of relationship added
5. Denominator Strength RefSet added to updated has_BoSS relationship to reflect normalisation
6. Unit of Use Size RefSet added to has_unit_of_use relationship
7. Example shows multiple TPUUs relating to one MPUU
8. CTPP to TP and TPP to TP relationship name changed.
9. Unit of Measure qualifier added to unit of use quantity.

Triphasil – 7 boxes

Substance: levonorgestrel

Substance: ethinyloestradiol

Substance: inert substance

MP: levonorgestrel + ethinyloestradiol

MP: inert substance

TP: Triphasil

MPUU: inert substance tablet

TPUU: Triphasil (inert substance) tablet

MPUU: levonorgestrel 50 microgram + ethinyloestradiol 30 microgram tablet

TPUU: Triphasil (levonorgestrel 50 microgram + ethinyloestradiol 30 microgram) tablet

MPUU: levonorgestrel 75 microgram + ethinyloestradiol 40 microgram tablet

TPUU: Triphasil (levonorgestrel 75 microgram + ethinyloestradiol 40 microgram) tablet

MPUU: levonorgestrel 125 microgram + ethinyloestradiol 30 microgram tablet

TPUU: Triphasil (levonorgestrel 125 microgram + ethinyloestradiol 30 microgram) tablet

TPP: Triphasil, 112 tablets [4 x 28 tablets]

CTPP: Triphasil, 112 tablets [4 x 28 tablets], blister pack

CTPP: Triphasil, 28 tablets, blister pack

MPP: levonorgestrel 50 microgram + ethinyloestradiol 30 microgram tablet [6 tablets] (&) levonorgestrel 75 microgram + ethinyloestradiol 40 microgram tablet [5 tablets] (&) levonorgestrel 125 microgram + ethinyloestradiol 30 microgram tablet [10 tablets] (&) inert substance tablet [7 tablets], 28

MPP: levonorgestrel 50 microgram + ethinyloestradiol 30 microgram tablet [24 tablets] (&) levonorgestrel 75 microgram + ethinyloestradiol 40 microgram tablet [20 tablets] (&) levonorgestrel 125 microgram + ethinyloestradiol 30 microgram tablet [40 tablets] (&) inert substance tablet [28 tablets], 112 [4 x 28 tablets]

Container: blister pack

unit of use quantity: 10

unit of use quantity: 5

unit of use quantity: 6

unit of use quantity: 7

subpack quantity: 4

has intended active ingredient

is a

has MPUU

has TP

has TPUU

has TPP

has subpack

has container type

Summary of Changes

1. MP to Substance has_ingredient relationship name updated.

2. MPUU to MP ingredient relationship added to inert tablet.

3. CTPP has subpack relationship added.

4. Removed Form, Unit of Use, Unit of Use Size and Unit of Measure qualifier for Unit of Use Quantity to improve clarity. MPUU Substance relationships have also been removed.

5. CTPP to TP and TPP to TP relationship name changed.

6. Has TPUU relationship originates from the CTPP subpack to the TPUUs.

Nexium Hp 7 – 7 boxes

MP
amoxycillin

MP
clarithromycin

MP
esomeprazole

TP
Nexium Hp 7

TP
Nexium

TP
Klacid

TP
Amoxil

is a

MPUU
amoxycillin 500 mg capsule

MPUU
clarithromycin 500 mg tablet

MPUU
esomeprazole 20 mg tablet

TPUU
Amoxil (amoxycillin 500 mg) capsule

TPUU
Klacid (clarithromycin 500 mg) tablet

TPUU
Nexium (esomeprazole 20 mg) tablet: enteric-coated

has TP

has TPUU

has MPUU

unit of use quantity
28

unit of use quantity
14

unit of use quantity
14

MPP
amoxycillin 500 mg capsule, 28

MPP
esomeprazole 20 mg tablet, 14

MPP
clarithromycin 500 mg tablet, 14

MPP
esomeprazole 20 mg tablet [14 tablets] (&) clarithromycin 500 mg tablet [14 tablets] (&) amoxycillin 500 mg capsule [28 capsules], 1 pack

has component pack

Container
blister pack

Container
blister pack

Container
blister pack

has container type

CTPP
Nexium 20 mg tablet: enteric-coated, 14, blister pack

CTPP
Klacid 500 mg tablet, 14, blister pack

CTPP
Amoxil 500 mg capsule, 28, blister pack

has TPUU

CTPP
Nexium Hp 7, 1 pack, composite pack

has container type

Container
composite pack

TPP
Nexium Hp 7, 1 pack

has TPP

Summary of Changes

1. Representation of has component pack from the CTPP superpack to its three CTPP component packs.

2. MPP representation of its three component packs added to example.

3. CTPP to TP and TPP to TP relationship name changed.

4. Removed Form, Unit of Use, Unit of Use Size and Unit of Measure qualifier for Unit of Use Quantity to improve clarity. MP and MPUU Substance relationships have also been removed.

5. Has TPUU relationship originates from each CTPP component pack to its TPUU.

6. Has TP relationship between CTPP component packs and TP added.

7. Has MPUU relationship originates from each MPP component pack to its MPUU.

Codral Day and Night – 7 boxes

Substance: codeine

Substance: paracetamol

Substance: phenylepherine

Substance: chlorpheniramine

has intended active ingredient

MP: codeine + paracetamol + phenylephrine

MP: chlorpheniramine + paracetamol + phenylephrine

is a

MPUU: codeine phosphate 9.5 mg + paracetamol 500 mg + phenylephrine hydrochloride 5 mg tablet

MPUU: chlorpheniramine maleate 2 mg + paracetamol 500 mg + phenylephrine hydrochloride 5 mg tablet

unit of use quantity: 12

has qualifier

Unit of Measure: tablet

has MPUU

MPP: codeine phosphate 9.5 mg + paracetamol 500 mg + phenylephrine hydrochloride 5 mg tablet [36 tablets] (&) chlorpheniramine maleate 2 mg + paracetamol 500 mg + phenylephrine hydrochloride 5 mg tablet [12 tablets], 48

unit of use quantity: 36

Unit of Measure: tablet

TP: Codral Day and Night Cold and Flu

has TP

TPUU: Codral Day and Night Cold and Flu (Day Tablet) (codeine phosphate 9.5 mg + paracetamol 500 mg + phenylephrine hydrochloride 5 mg) tablet

TPUU: Codral Day and Night Cold and Flu (Night Tablet) (chlorpheniramine maleate 2 mg + paracetamol 500 mg + phenylephrine hydrochloride 5 mg) tablet

has TPUU

TPP: Codral Day and Night Cold and Flu (36 x day tablets, 12 x night tablets), 48

has TPP

Container: blister pack

has container type

CTPP: Codral Day and Night Cold and Flu (36 x day tablets, 12 x night tablets), 48, blister pack

Summary of Changes

1. CTPP to TP and TPP to TP relationship name changed.

2. Removed Form, Unit of Use and Unit of Use Size to improve clarity. MPUU Substance relationships have also been removed.

3. Subpacks are only represented for oral contraceptives and hormone replacement therapies therefore subpacks are not represented in this example.

ZolaCos CP – 7 boxes



Summary of Changes

1. Representation of has component pack from the CTPP superpack to its two CTPP component packs.

2. MPP representation of its two component packs added to example.

3. CTPP to TP and TPP to TP relationship name changed.

4. Removed Form, Unit of Use and Unit of Use Size to improve clarity. MP and MPUU Substance relationships have also been removed.

5. Has TPUU relationship originates from each CTPP component pack to its TPUU.

6. Has TP relationship between CTPP component packs and TP added.

7. Has MPUU relationship originates from each MPP component pack to its MPUU.

Didrocal – 7 boxes



Summary of Changes

1. Representation of has component pack from the CTPP superpack to its two CTPP component packs.

2. MPP representation of its two component packs added to example.

3. CTPP to TP and TPP to TP relationship name changed.

4. CTPP component pack of calcium carbonate (Sanofi-Aventis) is available only as a component of the Didrocal combination pack. It is not available as a standalone product.

5. Removed Form, Unit of Use and Unit of Use Size to improve clarity. MP and MPUU Substance relationships have also been removed.

6. Has TPUU relationship originates from each CTPP component pack to its TPUU.

8. Has MPUU relationship originates from each MPP component pack to its MPUU.

8. Has TP relationship between CTPP component packs and TP added.

9. Superpack CTPP and TPP terms amended to reflect Didrocal as a combination pack.